FDA drafts guidance on genome editing, CAR T cell therapies

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)Clinical TrialsNorth AmericaProduct Lifecycle